• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Tango Therapeutics Inc.

    6/13/25 5:25:29 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TNGX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Tango Therapeutics, Inc.

    (Name of Issuer)


    Common stock, par value $0.001 per share (the "Shares")

    (Title of Class of Securities)


    87583X109

    (CUSIP Number)


    06/06/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Farallon Capital Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,145,398.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,145,398.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,145,398.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.1 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Farallon Capital Institutional Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,627,113.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,627,113.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,627,113.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.5 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Farallon Capital Institutional Partners II, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    351,630.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    351,630.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    351,630.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.3 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Farallon Capital Institutional Partners III, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    262,855.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    262,855.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    262,855.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.2 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Four Crossings Institutional Partners V, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.30
    6Shared Voting Power

    334,426.00
    7Sole Dispositive Power

    0.30
    8Shared Dispositive Power

    334,426.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    334,426.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.3 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Farallon Capital Offshore Investors II, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,984,329.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,984,329.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,984,329.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.8 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Farallon Capital F5 Master I, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    276,302.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    276,302.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    276,302.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.3 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Farallon Capital (AM) Investors, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    199,947.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    199,947.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    199,947.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.2 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Farallon Partners, L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,905,698.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,905,698.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,905,698.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Farallon Institutional (GP) V, L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    334,426.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    334,426.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    334,426.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.3 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Farallon F5 (GP), L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    276,302.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    276,302.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    276,302.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.3 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Dapice Joshua J.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,182,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,182,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,182,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Dreyfuss, Philip D.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,182,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,182,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,182,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Dunn Hannah E.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,182,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,182,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,182,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Fried, Richard B
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,182,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,182,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,182,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Gehani, Varun N.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,182,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,182,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,182,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Giauque, Nicolas
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    FRANCE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,182,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,182,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,182,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Kim, David T.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,182,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,182,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,182,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Linn, Michael G.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,182,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,182,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,182,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Luo Patrick (Cheng)
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CHINA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,182,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,182,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,182,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Patel, Rajiv A.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,182,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,182,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,182,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Roberts, Jr., Thomas G.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,182,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,182,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,182,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Saito Edric C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,182,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,182,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,182,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Seybold, William
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,182,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,182,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,182,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Short Daniel S.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,182,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,182,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,182,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Spokes, Andrew J. M.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,182,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,182,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,182,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Warren, John R.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,182,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,182,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,182,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    87583X109


    1Names of Reporting Persons

    Wehrly, Mark C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,182,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,182,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,182,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Tango Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    201 Brookline Avenue, Suite 901, Boston, Massachusetts, 02215
    Item 2. 
    (a)Name of person filing:

    This statement is filed by the entities and persons listed below, all of whom together are referred to herein as the "Reporting Persons". (i) Farallon Capital Partners, L.P., a California limited partnership ("FCP"), with respect to the Shares held by it; (ii) Farallon Capital Institutional Partners, L.P., a California limited partnership ("FCIP"), with respect to the Shares held by it; (iii) Farallon Capital Institutional Partners II, L.P., a California limited partnership ("FCIP II"), with respect to the Shares held by it; (iv) Farallon Capital Institutional Partners III, L.P., a Delaware limited partnership ("FCIP III"), with respect to the Shares held by it; (v) Four Crossings Institutional Partners V, L.P., a Delaware limited partnership ("FCIP V"), with respect to the Shares held by it; (vi) Farallon Capital Offshore Investors II, L.P., a Cayman Islands exempted limited partnership ("FCOI II"), with respect to the Shares held by it; (vii) Farallon Capital F5 Master I, L.P., a Cayman Islands exempted limited partnership ("F5MI"), with respect to the Shares held by it; and (viii) Farallon Capital (AM) Investors, L.P., a Delaware limited partnership ("FCAMI"), with respect to the Shares held by it. FCP, FCIP, FCIP II, FCIP III, FCIP V, FCOI II, F5MI and FCAMI are together referred to herein as the "Farallon Funds." (ix) Farallon Partners, L.L.C., a Delaware limited liability company (the "Farallon General Partner"), which is (i) the general partner of each of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI, and (ii) the sole member of the FCIP V General Partner (as defined below), with respect to the Shares held by each of the Farallon Funds other than F5MI. (x) Farallon Institutional (GP) V, L.L.C., a Delaware limited liability company (the "FCIP V General Partner"), which is the general partner of FCIP V, with respect to the Shares held by FCIP V. (xi) Farallon F5 (GP), L.L.C., a Delaware limited liability company (the "F5MI General Partner"), which is the general partner of F5MI, with respect to the Shares held by F5MI. (xii) The following persons, each of whom is a managing member or senior managing member, as the case may be, of the Farallon General Partner, and a manager or senior manager, as the case may be, of the FCIP V General Partner and the F5MI General Partner, with respect to the Shares held by the Farallon Funds: Joshua J. Dapice ("Dapice"); Philip D. Dreyfuss ("Dreyfuss"); Hannah E. Dunn ("Dunn"); Richard B. Fried ("Fried"); Varun N. Gehani ("Gehani"); Nicolas Giauque ("Giauque"); David T. Kim ("Kim"); Michael G. Linn ("Linn"); Patrick (Cheng) Luo ("Luo"); Rajiv A. Patel ("Patel"); Thomas G. Roberts, Jr. ("Roberts"); Edric C. Saito ("Saito"); William Seybold ("Seybold"); Daniel S. Short ("Short"); Andrew J. M. Spokes ("Spokes"); John R. Warren ("Warren"); and Mark C. Wehrly ("Wehrly"). Dapice, Dreyfuss, Dunn, Fried, Gehani, Giauque, Kim, Linn, Luo, Patel, Roberts, Saito, Seybold, Short, Spokes, Warren and Wehrly are together referred to herein as the "Farallon Individual Reporting Persons."
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San Francisco, California 94111.
    (c)Citizenship:

    The citizenship of each of the Farallon Funds, the Farallon General Partner, the FCIP V General Partner and the F5MI General Partner is set forth above. Each of the Farallon Individual Reporting Persons, other than Giauque, Luo and Spokes, is a citizen of the United States. Giauque is a citizen of France. Luo is a citizen of China. Spokes is a citizen of the United Kingdom.
    (d)Title of class of securities:

    Common stock, par value $0.001 per share (the "Shares")
    (e)CUSIP No.:

    87583X109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person. The Shares reported hereby for the respective Farallon Funds are held directly by the respective Farallon Funds. The Farallon General Partner, as the general partner of each of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI, and as the sole member of the FCIP V General Partner, may be deemed to be a beneficial owner of such Shares held by the Farallon Funds other than F5MI. The FCIP V General Partner, as the general partner of FCIP V, may be deemed to be a beneficial owner of such Shares held by FCIP V. The F5MI General Partner, as the general partner of F5MI, may be deemed to be a beneficial owner of such Shares held by F5MI. Each of the Farallon Individual Reporting Persons, as a managing member or senior managing member, as the case may be, of the Farallon General Partner, and as a manager or senior manager, as the case may be, of the FCIP V General Partner and the F5MI General Partner, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of such Shares held by the Farallon Funds. Each of the Farallon General Partner, the FCIP V General Partner, the F5MI General Partner and the Farallon Individual Reporting Persons hereby disclaims any beneficial ownership of any such Shares.
    (b)Percent of class:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

     (ii) Shared power to vote or to direct the vote:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    The Reporting Persons are filing this Schedule 13G pursuant to Section 240.13d-1(c). The Reporting Persons neither disclaim nor affirm the existence of a group among them. Each Reporting Person is a beneficial owner only of the securities reported by it on its cover page.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Farallon Capital Partners, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:06/13/2025
     
    Farallon Capital Institutional Partners, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:06/13/2025
     
    Farallon Capital Institutional Partners II, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:06/13/2025
     
    Farallon Capital Institutional Partners III, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:06/13/2025
     
    Four Crossings Institutional Partners V, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager of its General Partner
    Date:06/13/2025
     
    Farallon Capital Offshore Investors II, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:06/13/2025
     
    Farallon Capital F5 Master I, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager of its General Partner
    Date:06/13/2025
     
    Farallon Capital (AM) Investors, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:06/13/2025
     
    Farallon Partners, L.L.C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member
    Date:06/13/2025
     
    Farallon Institutional (GP) V, L.L.C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager
    Date:06/13/2025
     
    Farallon F5 (GP), L.L.C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager
    Date:06/13/2025
     
    Dapice Joshua J.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/13/2025
     
    Dreyfuss, Philip D.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/13/2025
     
    Dunn Hannah E.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn
    Date:06/13/2025
     
    Fried, Richard B
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/13/2025
     
    Gehani, Varun N.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/13/2025
     
    Giauque, Nicolas
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/13/2025
     
    Kim, David T.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/13/2025
     
    Linn, Michael G.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/13/2025
     
    Luo Patrick (Cheng)
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/13/2025
     
    Patel, Rajiv A.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/13/2025
     
    Roberts, Jr., Thomas G.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/13/2025
     
    Saito Edric C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/13/2025
     
    Seybold, William
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/13/2025
     
    Short Daniel S.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/13/2025
     
    Spokes, Andrew J. M.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/13/2025
     
    Warren, John R.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/13/2025
     
    Wehrly, Mark C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/13/2025
    Exhibit Information

    Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

    Get the next $TNGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TNGX

    DatePrice TargetRatingAnalyst
    7/17/2024$19.00Buy
    Jefferies
    4/4/2024Overweight
    Cantor Fitzgerald
    2/12/2024$18.00Overweight
    Piper Sandler
    12/8/2023$16.00Buy
    B. Riley Securities
    10/20/2022$10.00Neutral → Buy
    H.C. Wainwright
    9/20/2021$25.00Outperform
    SVB Leerink
    9/7/2021$12.00Outperform
    Wedbush
    9/7/2021$20.00Outperform
    Wedbush
    More analyst ratings

    $TNGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

      BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 10 at 3:20-3:55 PM ET. The live webcast will be available under the "Events & Presentations" tab on the "Investors" page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discoveri

      5/27/25 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

      BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the TNG456 Phase 1/2 trial in patients with MTAP-deleted solid tumors, with a focus on glioblastoma (GBM). TNG456 is a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor. "Dosing the first patient in the TNG456 Phase 1/2 trial marks a significant step for us and for patients with MTAP-deleted GBM," said Adam Crystal, M.D., Ph.D., President, Research and Development of Tango Therapeutics. "People with GBM currently have few tr

      5/21/25 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

      – Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million as of March 31, 2025; cash runway extended into 1Q 2027 with reduction of preclinical spend –   BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2025, and provided business highlights. "Accumulating data continue to support TNG462 as the potent

      5/12/25 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tango Therapeutics Inc.

      SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

      11/20/24 4:24:26 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tango Therapeutics Inc.

      SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

      11/7/24 9:35:56 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tango Therapeutics Inc.

      SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

      10/28/24 9:22:40 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Tango Therapeutics with a new price target

      Jefferies initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $19.00

      7/17/24 8:01:05 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Tango Therapeutics

      Cantor Fitzgerald initiated coverage of Tango Therapeutics with a rating of Overweight

      4/4/24 8:18:34 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Tango Therapeutics with a new price target

      Piper Sandler initiated coverage of Tango Therapeutics with a rating of Overweight and set a new price target of $18.00

      2/12/24 6:28:21 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rothenberg Mace bought $74,000 worth of shares (20,000 units at $3.70), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

      4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

      11/18/24 7:20:03 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Boxer Capital, Llc bought $8,722,500 worth of shares (1,250,000 units at $6.98) (SEC Form 4) (Amendment)

      4/A - Tango Therapeutics, Inc. (0001819133) (Issuer)

      10/17/23 7:41:18 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Boxer Capital, Llc bought $8,722,500 worth of shares (1,250,000 units at $6.98) (SEC Form 4)

      4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

      10/17/23 6:04:34 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNGX
    Financials

    Live finance-specific insights

    See more
    • Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more info

      5/1/25 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

      – Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 – – Dose escalation ongoing in phase 1/2 trial of CoREST inhibitor TNG260 and pembrolizumab in patients with STK11 mutant solid tumors – – FDA Fast Track designation granted for TNG348, a novel USP1 inhibitor, for the treatment of BRCA1/2-mutant breast and ovarian cancer; phase 1/2 clinical trial initiation expected 1H 2024 – – Kanishka Pothula, partner at Nextech Ventures, appointed to Board of Directors, replacing Reid Huber, Ph.D., partner at Third Rock Ventures – – Strong cash position of $360 million; cash runway into 2026 expected to fund all clini

      11/8/23 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

      Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointmen

      8/28/23 7:00:57 AM ET
      $EDIT
      $MDNA
      $TNGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

      – Dose escalation update from ongoing TNG908 clinical trial confirms proof-of-mechanism for MTA-cooperative tumor-selective PRMT5 inhibition in MTAP-deleted cancers – – FDA clears IND application for TNG260, a first-in-class CoREST complex inhibitor for the treatment of STK11-mutant cancers – – Fast Track designation granted by FDA for TNG260 + anti-PD-1 antibody for the treatment of patients with advanced NSCLC with STK11-loss of function mutations – – Strong cash position of $334 million expected to support advancing precision oncology pipeline into 2026 – BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed

      5/9/23 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Peters Malte was granted 6,250 shares, increasing direct ownership by 56% to 17,500 units (SEC Form 4)

      4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

      6/9/25 5:51:20 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Calhoun Lesley Ann was granted 6,250 shares, increasing direct ownership by 100% to 12,500 units (SEC Form 4)

      4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

      6/9/25 5:50:27 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Rothenberg Mace was granted 6,250 shares, increasing direct ownership by 20% to 37,500 units (SEC Form 4)

      4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

      6/9/25 5:47:25 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNGX
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Tango Therapeutics Inc.

      SCHEDULE 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

      6/13/25 5:25:29 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Tango Therapeutics Inc.

      8-K - Tango Therapeutics, Inc. (0001819133) (Filer)

      6/6/25 4:02:30 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Tango Therapeutics Inc.

      EFFECT - Tango Therapeutics, Inc. (0001819133) (Filer)

      5/22/25 12:15:24 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care